Astellas Pharma Inc announced the European Commission (EC) has approved a label extension for Xtandi (enzalutamide) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of adult men with high-risk biochemical recurrent (BCR) non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy
COMET-1 trial is initiated for cabozantinib from Exelixis Inc., and is a double-blind, placebo-controlled Phase III study that will include...
For chemotherapy-naïve patients, enzalutamide demonstrated a significant impact on overall survival compared to placebo
Merck Inc. announced that the Phase III KEYNOTE-921 trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival (OS) and radiographic progression-free survival (rPFS) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after...
Bristol-Myers Squibb Company reported results from the Phase III randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab)...
Key Points: ?Enzalutamide significantly reduced the risk of radiographic progression or death by 81% compared with placebo Enzalutamide demonstrated a significant...
Results of a Phase III trial of Zytiga (abiraterone acetate), from Janssen Biotech, confirm it offers a significant survival benefit...
Background: Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer.
Bristol-Myers Squibb Company announced data evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in patients with metastatic castration-resistant prostate cancer...